Over the past few days, the epidemic situation of the novel coronavirus in Hong Kong has changed dramatically, and the number of locally confirmed cases has surged. Hybribio Hong Kong Molecular Pathology Detection Center (HK-MPDC), as one of the designated testing agencies of the Hong Kong Department of Health, quickly joint the third time of COVID-19 nucleic acid testing.

Hybribio HK-MPDC was officially established in January 2013. In 2016, it obtained the international ISO15189:2012 molecular medicine qualification issued by the Hong Kong government. Hybribio HK-MPDC has excellent professional strength and is the first testing center in Hong Kong which obtained the qualification of Thermo Fisher Scientific's second generation sequencing service. It provides genetic testing services for many public and private hospitals in Hong Kong. It is also the Asia's medication guidance agency designated by Novartis, Pfizer, GlaxoSmithKline, and other six international pharmaceutical companies.

Nucleic acid detection is an important guarantee for the prevention and control of epidemics. With years of operation management and testing service capabilities, Hybribio HK-MPDC participated in the Hong Kong Health Protection Center's external quality assessment. The results are completely correct, demostrating that Hybribio HK-MPDC can provide strong testing support for Hong Kong's epidemic prevention and control. In an interview with Hong Kong media O1 News, Dr. Huang Libao, from Hybribio HK-MPDC, said that HK-MPDC responded to the government’s request and assumed social responsibility, excluding labor costs, and launched a preferential testing package in cooperation with the medical group, only hoping to help Hong Kong citizens get through the difficulties as soon as possible.

Hybribio Hong Kong Molecular Pathology Detection Center

Since the outbreak of the novel coronavirus epidemic, Hybribio has acted quickly and deployed uniformly. As of early July, more than 2 million cases have been tested. From the battles in the 30th of the Chinese New Year, to the support of the 10-day Wuhan General Assembly and Beijing’s support of the epidemic prevention and control warfare, etc., Hybribio has used its mature technology and service experience to build a protective shield against the epidemic for the people to the fullest. Government screening, resumption of work, re-entry to school and other relevant personnel testing.

The picture is from the Hong Kong SAR Government News Network

The integration of Guangdong, Hong Kong and Macao in the fight against epidemic is deemed to win the fight. As a novel coronavirus nucleic acid testing institution recognized and trusted by the Hong Kong government, Hybribio HK-MPDC is duty-bound, and will go all out to join the epidemic prevention and epidemic detection front line, invest more manpower and material to improve the detection capacity, in order to quickly expand the scale of detection. To help the Hong Kong government carry out large-scale screening, find out asymptomatic patients, block the source of the disease, cut off the chain of transmission, quickly control the epidemic from the root cause, and protect the health and safety of Hong Kong compatriots.